Vogenx joins the IPO queue to fund phase 2-stage metabolic drug
Vogenx has joined the growing queue for the Nasdaq, as the metabolic biotech eyes an IPO to fund its SGLT1 inhibitor. The Durham, North Carolina-based company has yet to set out how many shares it plans to offer or at what price. But top of the list of …